Comparison of survival rates between 3D conformal radiotherapy and intensity-modulated radiotherapy in patients with stage Ⅲ non&amp;ndash;small cell lung cancer

Kong, Moonkyoo; Hong, Seong Eon

doi:10.2147/ott.s124311

Cited by 8 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,5 The 5-year survival of stage IV NSCLC patients is as low as 1%. 6,7 Therefore, it is of great clinical significance to investigate the molecular mechanism of occurrence and development of NSCLC to improve the early diagnosis rate, predicting the prognosis, and improving the survival rate of patients.…”

Section: Introductionmentioning

confidence: 99%

“…Although the current therapeutical treatment for NSLCC including surgery, molecular‐targeted therapy, and chemotherapy has been progressed tremendously in the last several decades, the prognosis is still poor with high metastasis of the NSLCC . The 5‐year survival of stage IV NSCLC patients is as low as 1% . Therefore, it is of great clinical significance to investigate the molecular mechanism of occurrence and development of NSCLC to improve the early diagnosis rate, predicting the prognosis, and improving the survival rate of patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

lncRNA HNF1A‐AS1 modulates non–small cell lung cancer progression by targeting miR‐149‐5p/Cdk6

Liu

Chen

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Growing evidence have shown the important regulation of lncRNAs (long noncoding RNAs) in non–small cell lung cancer (NSCLC). lncRNA hepatocyte nuclear factor 1 homeobox A (HNF1A)‐antisense RNA 1 (AS1), an “oncogene”, was reported to regulate human tumors progression. However, the molecular mechanism of HNF1A‐AS1 involved in the development of NSCLC is still under investigation. In the current study, we found that HNF1A‐AS1 was relatively upregulated in both NSCLC patient tissues and cell lines. Functional studies established that overexpression of HNF1A‐AS1 promoted cell proliferation, cell cycle, invasion, and migration of NSCLC cells in vitro. The promotion abilities of HNF1A‐AS1 on NSCLC cell progression were suppressed via knockdown of HNF1A‐AS1. miR‐149‐5p was then proved to be a novel target of HNF1A‐AS1, whose expression was negatively correlated with HNF1A‐AS1 in NSCLC patient tissues and cell lines. HNF1A‐AS1 increased the expression of cyclin‐dependent kinase 6 (Cdk6) via sponging with miR‐149‐5p. Gain‐ and loss‐of‐functional studies indicated that HNF1A‐AS1 promoted NSCLC progression partially through inhibition of miR‐363‐3p and induction of Cdk6. Subcutaneous xenotransplanted tumor model confirmed that interference of HNF1A‐AS1 suppressed the tumorigenic ability of NSCLC via upregulation of miR‐149‐5p and downregulation of Cdk6 in vivo. In conclusion, our findings clarified the biologic significance of the HNF1A‐AS1/miR‐149‐5p/Cdk6 axis in NSCLC progression and provided novel evidence that HNF1A‐AS1 may be a new potential therapeutic target for the treatment of NSCLC.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

lncRNA HNF1A‐AS1 modulates non–small cell lung cancer progression by targeting miR‐149‐5p/Cdk6

Liu

Chen

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…The IMRT technique has been recently used in DRT for NSCLC, but it remains unclear that this ILAS is useful for predicting steroid-RP in DRT with IMRT. The difference of radiation dose distribution 28 and clinical outcomes 29 , 30 between 3DCRT and IMRT has also been reported. However, in this study, to homogenize the patient background, patients treated with the IMRT technique were eliminated.…”

Section: Discussionmentioning

confidence: 93%

Usefulness of Simple Original Interstitial Lung Abnormality Scores for Predicting Radiation Pneumonitis Requiring Steroidal Treatment After Definitive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

Kashihara

Nakayama

Ito

et al. 2021

Advances in Radiation Oncology

View full text Add to dashboard Cite

Purpose Adjuvant durvalumab has become a standard treatment after chemoradiation therapy for patients with locally advanced non-small cell lung cancer (LA-NSCLC). Accordingly, predicting radiation pneumonitis (RP) requiring steroidal treatment (steroid-RP) is of utmost importance because steroidal administration is reported to weaken the effectiveness of immunotherapy. However, grade 2 RP was used as an index of RP in previous studies, but it is an ambiguous definition because it includes not only steroid-RP but also a mild cough requiring only a cough medicine. Therefore, in this study, steroid-RP was used for evaluating RP, and the purpose of this study was to investigate predictive factors of steroid-RP, including original simple interstitial lung abnormality scores (ILASs). Methods and Materials A total of 145 patients with LA-NSCLC who received definitive radiation therapy (DRT) in our institution from January 2014 to May 2017 were identified. Original ILASs, performance status, age, respiratory function, Brinkman index, concurrent administration of chemotherapy, and dose–volume histogram metrics of the lung were analyzed to evaluate their association with steroid-RP. Additionally, 3 diagnostic radiologists evaluated the patients’ pre-DRT chest computed tomography images and determined the simple ILASs. ILASs were rated as follows: 0: none; 1: abnormality without honeycombing (ground-glass attenuation, fine reticular opacity, and microcysts); and 2: honeycombing. Results The median follow-up period was 729 days. Thirty-one patients (21.4%) experienced steroid-RP. In the univariate analysis, lung V5/V10/VS5, Brinkman index, and ILASs were significant predictive factors of steroid-RP. Additionally, multivariate analysis including Brinkman index ≥840, lung V5 ≥37%, and an ILAS ≥1 revealed that only an ILAS ( P = .001) was an independent predictive factor of steroid-RP. Conclusions The original simple ILAS was an easy-to-use tool and a significant predictive factor of steroid-RP in DRT in patients with LA-NSCLC.

show abstract

“…Comparison of 3D-CRT versus VMAT plans in the 9 patients treated by 3D-CRT showed a statistically significant difference only in terms of increased mean heart doses by 3D-CRT and increased V5 for bilateral lungs by VMAT. Though rates of radiation pneumonitis and radiation esophagitis have been proven to be lower in multiple studies with VMAT, 3D-CRT is the best available option in most LMIC (Low and Middle Income Countries) [7] , [8] , [26] , [27] , [28] .…”

Section: Discussionmentioning

confidence: 99%

“…18 F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) based treatment planning helps in this regard by both better tumour and nodal delineation, thus potentially sparing normal tissue. Multiple studies have shown dosimetric benefits of intensity modulated radiation therapy (IMRT) over 3-dimensional conformal radiotherapy (3D-CRT) but no overall survival benefit has been demonstrated [5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Challenges of radical chemoradiation planning in Stage III non-small-cell lung cancer: Can volumetric modulated arc radiotherapy overcome an unfavourable location?

Kapoor

Das

Miriyala

et al. 2020

Physics and Imaging in Radiation Oncology

View full text Add to dashboard Cite

Background and purpose: Radiotherapy treatment planning of radical doses for concurrent chemoradiation in Stage III non-small-cell lung cancer (NSCLC) presents many challenges. This dosimetric study aimed to analyse the impact of spatial location of tumour and nodal burden in limiting the achievement of normal organ constraints and the use of appropriate radiotherapy technique to address it. Materials and methods: Fifteen Stage III NSCLC patients underwent 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET)/computed tomography (CT) based treatment planning. VMAT (Volumetric Modulated Arc Radiotherapy) plans were made for all patients treated by 3D-CRT (3-Dimensional Conformal Radiotherapy). A binomial logistic regression was performed to ascertain the tumour and nodal characteristics that decreased the likelihood of being planned to 60 Gy. Results: Inability to achieve normal tissue constraints, particularly spinal cord dose to less than 50 Gy, during initial planning by the assigned treatment technique was the primary dose limiting factor in four patients (p = 0.02). Alternate VMAT plans could achieve the dose constraints where 3D-CRT was unsuccessful in patients with bulky central disease in two patients. This technique fell short when there was gross vertebral body erosion. Conclusions: For tumours with bulky central disease, VMAT should be preferred. With gross vertebral body erosion, even VMAT falls short if the planning target volume includes the spinal cord. In a subset of Stage III NSCLC upfront chemoradiation to radical doses may not be feasible.

show abstract

Comparison of survival rates between 3D conformal radiotherapy and intensity-modulated radiotherapy in patients with stage Ⅲ non–small cell lung cancer

Cited by 8 publications

References 20 publications

lncRNA HNF1A‐AS1 modulates non–small cell lung cancer progression by targeting miR‐149‐5p/Cdk6

lncRNA HNF1A‐AS1 modulates non–small cell lung cancer progression by targeting miR‐149‐5p/Cdk6

Usefulness of Simple Original Interstitial Lung Abnormality Scores for Predicting Radiation Pneumonitis Requiring Steroidal Treatment After Definitive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

Challenges of radical chemoradiation planning in Stage III non-small-cell lung cancer: Can volumetric modulated arc radiotherapy overcome an unfavourable location?

Contact Info

Product

Resources

About